Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Once therapeutic doses are reached, many people lose about 12 pounds per week
Clinical Evidence for Non-Diabetic GLP-1 Use The STEP trials (Semaglutide Treatment Effect in People with Obesity) enrolled participants without diabetes and demonstrated average weight loss of 1522% over 68 weeks compared to placebo
Among the 47.5 million Medicare Part D enrollees in 2023, 9.7 million enrollees met the clinical criteria for the Medicare GLP-1 Bridge in 2023, but less than half of this group3.8 million (39%)is estimated to be eligible for Bridge (Figure 2, Table 1)
There are many prescription alternatives with efficacy similar to that of GLP-1 pills
Tirzepatide is prescription-only and is not appropriate for everyone, including patients with certain thyroid cancer histories, MEN2, pancreatitis, pregnancy, or allergy to tirzepatide
US$ 27.26
US$ 22.58
US$ 24.42
US$ 29.87
US$ 26.62
US$ 22.31
US$ 21.62
